Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program

Form / Attachment / Pricing Sheet

This document contains Blanket Purchase Agreement (BPA) appendices and an Additional Discount Program (ADP) appendix related to the Uniform Formulary (UF) for Antihemophilic Agents (Non-Factor Agents). It outlines pricing structures and formulary scenarios for the May 2026 DoD P&T Meeting. Bidders are expected to provide pricing information based on these appendices.

• BPA Appendix: Details Uniform Formulary (UF) and Non-Formulary (NF) scenarios, including "Before-Step Therapy" and "After-Step Therapy" classifications. It specifies that prices per unit of measure will be the same for all package sizes within a given dispensing venue. Manufacturers are instructed to submit fully executed signature pages with quotes.
• ADP Appendix: Outlines the Additional Discount Program, focusing on non-FAMP (Federal Acquisition Regulation Part 22) pricing and refunds. It defines scenarios for Tier 2 (T2) and Tier 3 (T3) agents, including "Before-Step Therapy" and "After-Step Therapy." The appendix details calculations for total retail refunds based on non-FAMP prices and offered discounts.
• Quotes Due: April 2, 2026.
• P&T Committee Meeting: May 6-7, 2026.

This document is critical for bidders as it provides the framework for submitting pricing proposals for Antihemophilic Agents. It outlines the specific formulary categories, step therapy requirements, and discount structures that will be used for evaluation. Bidders must carefully review the scenarios and pricing calculations to ensure their quotes are competitive and compliant with DoD requirements. The "NO QUOTE" entries in the BPA appendix indicate areas where quotes may not be required or have not been submitted, while red highlighting in the ADP appendix signifies a need for quote confirmation.

Forms / Attachments / Pricing Sheets

This document contains pricing information and formulary details for Leukemia and Lymphoma Agents, specifically BCR-ABL Tyrosine Kinase Inhibitors, relevant to the May 2026 DoD P&T Meeting. It includes two main sheets: 'BPA' (Blanket Purchase Agreement) and 'ADP' (Additional Discount Program).

BPA Sheet:

• Lists Uniform Formulary (UF) and Non-Formulary (NF) scenarios for agents.
• Specifies "NO QUOTE" for all listed scenarios, indicating no current pricing is provided or required through this specific listing.
• Includes class and subclass notes regarding Prior Authorization (PA), special reimbursement methods, and Step Therapy.
• Quotes are due by April 2, 2026.

ADP (non-FAMP Discount) Sheet:

• Details scenarios for Tier 2 and Tier 3 agents.
• Outlines calculations for "Total Calculated Refund Per FCP" based on Non-FAMP Price, Additional Offered Refund, and Federal Ceiling Price (FCP).
• Indicates that cells highlighting red require confirmation of intent not to submit a quote.
• Quotes are due by April 2, 2026.

This document provides critical context for potential bidders regarding pricing structures, formulary placement, and reimbursement considerations for specific pharmaceutical agents. While the 'BPA' sheet indicates "NO QUOTE" for listed scenarios, the 'ADP' sheet details refund calculations, which are essential for understanding the financial aspects of participating in the DoD's pharmaceutical formulary. The due date for quotes is April 2, 2026.

Form / Attachment / Pricing Sheet

This document, titled "May 2026 PT Meeting Reporting.xlsx", contains detailed data related to pharmacy operations support, specifically focusing on antihemophilic and leukemia/lymphoma agents. It appears to be a data report rather than a solicitation or SOW. The data covers the period of January 2025 through December 2025 and includes dispensing quantities and equivalent 30-day prescriptions.

• Data Source: Military Health System (MHS) Pharmacy Data Transaction Service (PDTS).
• Content: Detailed breakdowns of dispensed quantities and 30-day equivalent prescriptions for specific drug classes (Antihemophilic Agents, Leukemia and Lymphoma Agents).
• Drug Categories: Includes data for drugs like HEMLIBRA (EMICIZUMAB-KXWH), BOSULIF (BOSUTINIB), GLEEVEC (IMATINIB MESYLATE), SPRYCEL (DASATINIB), TASIGNA (NILOTINIB HCL), and others.
• Limitations: The document notes limitations of the PDTS data for chronological functions and research, including unfulfilled prescriptions, changes in dispensing procedures (e.g., days supply), inability to distinguish acute vs. chronic use, and impact of mobile populations.
• Format: Data is presented in spreadsheet format, with specific sheets for "Antihemophilic History", "Antihemophilic Summary", "Antihemophilic NDC", "Leukemia History", "Leukemia Summary", and "Leukemia NDC".

This document provides historical data on drug utilization for specific therapeutic areas. Bidders interested in opportunities related to pharmacy operations, pharmaceutical supply chain management, or clinical support services may find this data useful for understanding past usage patterns, market demand, and the types of medications involved. It serves as a data-driven insight into the scope of potential future requirements within these therapeutic areas.

Solicitation / RFP / RFQ

This Request for Quotation (RFQ) seeks quotes for pharmaceutical agents to be considered for placement on the Department of Defense (DoD) Uniform Formulary (UF). The goal is to establish effective and efficient integrated pharmacy benefits for the Military Health System (MHS). This process may lead to the award of Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) Agreements.

• Manufacturers must submit price quotes for pharmaceutical agents.

• Quotes are for inclusion on the UF, and potentially for the Basic Core Formulary (BCF) or Extended Core Formulary (ECF).

• UF BPA quotes are for prices applicable to Military Treatment Facilities (MTF) and TRICARE Mail Order Pharmacy (TMOP).

• UF ADP quotes are for refunds applicable to pharmaceutical agents dispensed by TRICARE retail network pharmacies.

• Quotes must include all National Drug Code (NDC)-11 numbers for the agent, unless specific exclusions are approved.

• Pricing must be provided per unit of measure and per NDC-11 package.

• The UF BPA price quotes are to be held valid for 180 days.

• The UF ADP refund quotes are contingent upon the agent being placed on the UF (generic or formulary tier).

• The agreement period for UF BPA and UF ADP is subject to formulary status changes and potential termination.

• Key Dates:

  • Posting Date: February 5, 2026
  • Pre-Quotation Teleconference: February 11, 2026, 1:00 PM CST
  • Quotes Due: April 2, 2026, 12:00 PM CST
  • P&T Committee Meeting: May 6-7, 2026

• Submission Steps:

  1. Download Utilization Dataset and NDC Price List.
  2. Complete applicable pages and price appendices (Appendix 1 for all quotes; Appendix 2 for BPA quotes; Appendix 3 for ADP quotes).
  3. Submit signed quotes and NDC Price List to the RFQ Point of Contact.

• Evaluation: The DoD Pharmacy and Therapeutics (P&T) Committee will consider clinical effectiveness and cost-effectiveness, including UF BPA price quotes and UF ADP refund quotes, when recommending placement and cost-share tier classification for pharmaceutical agents.

• Manufacturers must have an existing FSS Contract Number / FSS Interim Agreement.

• Quotes are not accepted for generic (multi-source) pharmaceutical agents if existing Joint DoD/Veterans Administration (VA) contracts are in place.

• A pre-quotation teleconference will be held to address industry questions.

• One-on-one appointments with the Industry Technical Liaison are available upon request.

• The document includes definitions and acronyms relevant to the solicitation.

Form / Attachment / Pricing Sheet

This document is a "Price Appendix FAQ" that provides guidance to bidders on how to complete and submit pricing information for the opportunity. It clarifies the use of a spreadsheet with various tables for different National Drug Codes (NDCs).

• BPA (Section 1): Instructions for filling out the BPA pricing table, including entering Package Size, understanding how Price per NDC is calculated, and how to indicate if a quote is not being submitted for a condition set (red highlighting).
• ADP (Section 2): Guidance for the ADP pricing table, detailing how to input non-FAMP price and Current Annual Federal Ceiling Price, and how these inputs auto-populate subsequent cells. It also explains the calculation of Total Calculated Refund and how to indicate if a quote is not being submitted for a given Formulary Category.
• General Instructions: Bidders are instructed to fill only yellow cells, as other cells are locked. Formulary Notes at the top of the spreadsheet should be read for understanding the P&T committee's decision-making process.
• NDC Tables: Tables are provided for 10 different NDCs. Bidders only need to fill out tables relevant to their NDCs. For more than 10 NDCs, bidders should contact the POCs.

This FAQ is crucial for bidders to accurately complete the required pricing appendices. It outlines the specific data entry requirements, calculation methods, and how to signal non-participation in certain pricing scenarios. Contacting the POCs is advised for any questions or if more than 10 NDCs need to be quoted.